{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:40:50Z","timestamp":1760121650707},"reference-count":31,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,5,22]],"date-time":"2008-05-22T00:00:00Z","timestamp":1211414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective:<\/jats:title><jats:p>We assessed the outcomes in diabetic patients undergoing percutaneous coronary intervention (PCI) using sirolimus\u2010eluting stents (SES) as a function of treatment with glycoprotein (GP) IIb\/IIIa inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results:<\/jats:title><jats:p>Of 551 diabetic patients treated with a SES in nine trials (RAVEL, SIRIUS, E\u2010SIRIUS, C\u2010SIRIUS, REALITY, SVELTE, DIRECT, SIRIUS 2.25, and SIRIUS 4.0), 187 patients (33.9%) were administered GP IIb\/IIIa inhibitors during PCI. GP IIb\/IIIa blockade was associated with lower rates of myocardial infarction (MI) at 30 days (1.1% vs. 3.3%, <jats:italic>P<\/jats:italic> = 0.12) and at 1 year (1.1% vs. 4.7%, <jats:italic>P<\/jats:italic> = 0.04), and composite endpoint of cardiac death\/MI at 1 year (2.2% vs. 6.2%, <jats:italic>P<\/jats:italic> = 0.05). Benefit from GP IIb\/IIIa inhibitors was confined to 128 insulin\u2010treated diabetics who had remarkable reduction in MI (0.0% vs. 6.3%, <jats:italic>P<\/jats:italic> = 0.04) and cardiac death\/MI at 30 days (0.0% vs. 7.6%, <jats:italic>P<\/jats:italic> = 0.05) and at 1\u2010year (0.0% vs. 13.4%, <jats:italic>P<\/jats:italic> = 0.01 and 0.0% vs. 15.7%, <jats:italic>P<\/jats:italic> = 0.0005, respectively). When treated with GP IIb\/IIIa inhibitors, insulin\u2010requiring diabetics had similar rates of 1\u2010year death\/MI when compared with the nondiabetic patients (0% vs. 4.7%, <jats:italic>P<\/jats:italic> = 0.13, respectively). There were no significant differences in outcomes as a function of GP IIb\/IIIa blockade in diabetics not treated with insulin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>In this analysis, outcomes of insulin requiring diabetic patients undergoing PCI with SES were considerably improved with adjunctive GP IIb\/IIIa inhibitors by decreasing the rates of MI and composite endpoint of cardiac death\/MI. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ccd.21548","type":"journal-article","created":{"date-parts":[[2008,5,23]],"date-time":"2008-05-23T00:46:18Z","timestamp":1211503578000},"page":"896-906","source":"Crossref","is-referenced-by-count":5,"title":["Impact of platelet glycoprotein IIb\/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus\u2010eluting stents"],"prefix":"10.1002","volume":"71","author":[{"given":"Eugenia","family":"Nikolsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick","family":"Schampaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Claude","family":"Morice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Schofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Eduardo","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingbo","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis J.","family":"Donohoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Moses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin B.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,5,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03290450033020"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.4.979"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.18.2180"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90007-8"},{"key":"e_1_2_6_6_2","first-page":"436","article-title":"The PURSUIT Trial Investigators. Platelet glycoprotein IIb\/IIIa in unstable angina: Receptor suppression using integrilin therapy","volume":"339","author":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","year":"1998","journal-title":"N Engl J Med"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106213442502"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00650-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4801.100029"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000148956.93631.4D"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012843"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035071"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14462-5"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.01.024"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.8.895"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21162"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.02.025"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.06.047"},{"issue":"7","key":"e_1_2_6_19_2","first-page":"469","article-title":"on behalf of the SIRIUS 4.0 Investigators. The 4.0 mm sirolimus\u2010eluting BX VELOCITY\u2122 stent: Procedural, clinical and angiographic outcomes transcatheter cardiovascular therapeutics, Washington, September 2005","volume":"96","author":"Baim D","year":"2005","journal-title":"Am J Cardiol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000018123.02672.C7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00242-8"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050717"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00342-2"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(98)00050-4"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1990.tb02264.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1002650"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.104.2.163"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01124.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.7.1656"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.8.799"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000116752.12261.D4"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00035-2"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.21548","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.21548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T21:24:15Z","timestamp":1696973055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.21548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,22]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1002\/ccd.21548"],"URL":"https:\/\/doi.org\/10.1002\/ccd.21548","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,22]]}}}